These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22873189)

  • 1. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations.
    Stancliff S; Joseph H; Fong C; Furst T; Comer SD; Roux P
    J Addict Dis; 2012; 31(3):278-87. PubMed ID: 22873189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.
    Carter J; Zevin B; Lum PJ
    Addict Sci Clin Pract; 2019 May; 14(1):20. PubMed ID: 31060600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
    Schackman BR; Leff JA; Polsky D; Moore BA; Fiellin DA
    J Gen Intern Med; 2012 Jun; 27(6):669-76. PubMed ID: 22215271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suboxone misuse along the opiate maintenance treatment pathway.
    Furst RT
    J Addict Dis; 2013; 32(1):53-67. PubMed ID: 23480248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
    Altice FL; Bruce RD; Lucas GM; Lum PJ; Korthuis PT; Flanigan TP; Cunningham CO; Sullivan LE; Vergara-Rodriguez P; Fiellin DA; Cajina A; Botsko M; Nandi V; Gourevitch MN; Finkelstein R;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S22-32. PubMed ID: 21317590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
    Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
    Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.
    Korthuis PT; Fiellin DA; Fu R; Lum PJ; Altice FL; Sohler N; Tozzi MJ; Asch SM; Botsko M; Fishl M; Flanigan TP; Boverman J; McCarty D;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S83-90. PubMed ID: 21317600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.
    Lucas GM; Young A; Donnell D; Richardson P; Aramrattana A; Shao Y; Ruan Y; Liu W; Fu L; Ma J; Celentano DD; Metzger D; Jackson JB; Burns D;
    Drug Alcohol Depend; 2014 Sep; 142():139-45. PubMed ID: 24999060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
    Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK
    J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
    Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
    Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of buprenorphine dosage adequacy in opioid receptor agonist substitution therapy for heroin dependence: first use of the BUprenorphine-naloxone Dosage Adequacy eVAluation (BUDAVA) questionnaire.
    D'Amore A; Romano F; Biancolillo V; Lauro G; Armenante C; Pizzirusso A; Del Tufo S; Ruoppolo C; Auriemma F; Cassese F; Oliva P; Amato P
    Clin Drug Investig; 2012 Jul; 32(7):427-32. PubMed ID: 22559256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).
    Potter JS; Marino EN; Hillhouse MP; Nielsen S; Wiest K; Canamar CP; Martin JA; Ang A; Baker R; Saxon AJ; Ling W
    J Stud Alcohol Drugs; 2013 Jul; 74(4):605-13. PubMed ID: 23739025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.
    Fox AD; Chamberlain A; Sohler NL; Frost T; Cunningham CO
    J Subst Abuse Treat; 2015 Jan; 48(1):112-6. PubMed ID: 25205666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.
    Fiellin DA; Weiss L; Botsko M; Egan JE; Altice FL; Bazerman LB; Chaudhry A; Cunningham CO; Gourevitch MN; Lum PJ; Sullivan LE; Schottenfeld RS; O'Connor PG;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(0 1):S33-8. PubMed ID: 21317592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers.
    Woodcock EA; Lundahl LH; Greenwald MK
    Drug Alcohol Depend; 2015 Jan; 146():89-96. PubMed ID: 25479914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts.
    Jain K; Jain R; Dhawan A
    J Opioid Manag; 2011; 7(1):11-20. PubMed ID: 21434580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care.
    Egan JE; Netherland J; Gass J; Finkelstein R; Weiss L;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S46-53. PubMed ID: 21317594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.